Alphamab Oncology (09966.HK) Latest Company News

Aug 30, 2026, 16:45 UTC
Alphamab Oncology announced a resolution to repurchase its own shares from the open market, with a maximum amount of 80 million HKD.
Source:
- aastocks.com
Aug 27, 2026, 18:02 UTC
Alphamab Oncology (09966.HK) reported an interim net loss of 40.46 million RMB for the six months ended June 2026, compared with a net profit of 21.58 million RMB in the same period last year, with revenue down 15.1% year-on-year to 271 million RMB.
Source:
- aastocks.com
Aug 18, 2026, 13:04 UTC
China's National Medical Products Administration accepted the new drug application for KN026 combined with HB1801 for first-line treatment of advanced breast cancer, developed by CSPC Group's subsidiary Jinmantebio and Alphamab Oncology, and granted priority review.
Source:
- aastocks.com
Aug 4, 2026, 10:07 UTC
Alphamab Oncology and CSPC Pharmaceutical Group subsidiary Jinmantebio's new drug application for anlotinib combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer has been accepted by China's National Medical Products Administration and included in priority review.
Source:
- aastocks.com
- aastocks.com
Aug 4, 2026, 00:45 UTC
Jiangsu Alphamab (subsidiary of Alphamab Oncology) granted Pathos AI exclusive rights to develop, manufacture, and commercialize JSKN016 outside mainland China, Hong Kong, Macau, and Taiwan under a licensing agreement.
Source:
Aug 3, 2026, 14:44 UTC
Alphamab Oncology's JSKN033, a high-concentration subcutaneous compound formulation of a bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, was approved by the Center for Drug Evaluation of China's National Medical Products Administration to conduct a Phase III clinical study as monotherapy for recurrent or metastatic cervical cancer that has failed platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment.
Source:
- aastocks.com

09966.HK

Alphamab Oncology announced a resolution to repurchase its own shares from the open market, with a maximum amount of 80 million HKD.

Alphamab Oncology (09966.HK) reported an interim net loss of 40.46 million RMB for the six months ended June 2026, compared with a net profit of 21.58 million RMB in the same period last year, with revenue down 15.1% year-on-year to 271 million RMB.

China's National Medical Products Administration accepted the new drug application for KN026 combined with HB1801 for first-line treatment of advanced breast cancer, developed by CSPC Group's subsidiary Jinmantebio and Alphamab Oncology, and granted priority review.

Alphamab Oncology and CSPC Pharmaceutical Group subsidiary Jinmantebio's new drug application for anlotinib combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer has been accepted by China's National Medical Products Administration and included in priority review.

Jiangsu Alphamab (subsidiary of Alphamab Oncology) granted Pathos AI exclusive rights to develop, manufacture, and commercialize JSKN016 outside mainland China, Hong Kong, Macau, and Taiwan under a licensing agreement.